ImmuPharma (LON:IMM) Shares Up 36.5% - Should You Buy?

Key Points

• ImmuPharma's shares surged by 36.5% during mid-day trading, reaching a high of GBX 12.50 ($0.17) after closing at GBX 8.79 ($0.12).
• The company's market capitalization stands at £59.97 million, with a notably high P/E ratio of -1,348.31 and a beta of 1.53.
• ImmuPharma, known for developing peptide-based therapeutics, reported negative earnings per share of GBX (0.38) for the last quarter, while analysts project an EPS of -339 for the current fiscal year.

ImmuPharma plc (LON:IMM - Get Free Report) shares traded up 36.5% during mid-day trading on Tuesday . The company traded as high as GBX 12.50 ($0.17) and last traded at GBX 12 ($0.16). 15,680,309 shares traded hands during trading, an increase of 82% from the average session volume of 8,607,628 shares. The stock had previously closed at GBX 8.79 ($0.12).

ImmuPharma Stock Performance

The firm has a 50 day simple moving average of GBX 5.30 and a 200 day simple moving average of GBX 3.58. The firm has a market cap of £59.97 million, a P/E ratio of -1,348.31 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. Sell-side analysts predict that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.